from Reuters: Health News https://reut.rs/2IUZsur
via IFTTT
Tuesday, April 30, 2019
Novartis's Sandoz strikes deal for biosimilar of Herceptin
Novartis's Sandoz division has struck a deal with Taiwan's EirGenix Inc to market a biosimilar version of Roche's Herceptin that is now in late-stage development to treat some cancer tumors.
from Reuters: Health News https://reut.rs/2IUZsur
via IFTTT
from Reuters: Health News https://reut.rs/2IUZsur
via IFTTT
0 comments:
Post a Comment